Home Cart Sign in  
Chemical Structure| 1034895-42-5 Chemical Structure| 1034895-42-5

Structure of 9-ING-41
CAS No.: 1034895-42-5

Chemical Structure| 1034895-42-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

9-ING-41 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with antitumor activity. 9-ING-41 induces apoptosis and cell cycle arrest at prophase by targeting centrosomes and microtubule-bound GSK3β.

Synonyms: Elraglusib

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 9-ING-41

CAS No. :1034895-42-5
Formula : C22H13FN2O5
M.W : 404.35
SMILES Code : O=C(C(C1=COC2=CC=C(F)C=C12)=C3C4=CN(C)C5=C4C=C6C(OCO6)=C5)NC3=O
Synonyms :
Elraglusib
MDL No. :MFCD16495778
InChI Key :FARXPFGGGGLENU-UHFFFAOYSA-N
Pubchem ID :44582816

Safety of 9-ING-41

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Related Pathways of 9-ING-41

PI3K-AKT
Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MCF10A 0.5 μM 72 h No significant effect on the growth of non-tumorigenic mammary epithelial cells Cancer Lett. 2016 Oct 1;380(2):384-392
MDA-MB-231/LM2-4 2 μM 72 h Inhibition of GSK-3 activity, reducing breast cancer cell survival Cancer Lett. 2016 Oct 1;380(2):384-392
SKBR3 0.25 μM 72 h Inhibition of GSK-3 activity, reducing breast cancer cell survival Cancer Lett. 2016 Oct 1;380(2):384-392
MDA-MB-468 0.5 μM 72 h Inhibition of GSK-3 activity, reducing breast cancer cell survival Cancer Lett. 2016 Oct 1;380(2):384-392
HH cells 1-5 µM 72 h Assess cell viability and induce apoptosis, results showed Elraglusib reduced cell viability and induced apoptosis Cell Commun Signal. 2023 Jun 14;21(1):131.
Karpas-299 cells 1-5 µM 72 h Assess cell viability and induce apoptosis, results showed Elraglusib reduced cell viability and induced apoptosis Cell Commun Signal. 2023 Jun 14;21(1):131.
HS-Sultan cells 1-5 µM 72 h Assess cell viability and induce apoptosis, results showed Elraglusib reduced cell viability and induced apoptosis Cell Commun Signal. 2023 Jun 14;21(1):131.
Renal cancer cell line KU19-20 0.5-50 µM 96 h 9-ING-41 alone induced cell cycle arrest and apoptosis, and inhibited the proliferation of renal cancer cells. Int J Mol Med. 2020 Feb;45(2):315-323
Renal cancer cell line KRCY 0.5-50 µM 96 h 9-ING-41 alone induced cell cycle arrest and apoptosis, and inhibited the proliferation of renal cancer cells. Int J Mol Med. 2020 Feb;45(2):315-323
Renal cancer cell line Caki-1 0.5-50 µM 96 h 9-ING-41 alone induced cell cycle arrest and apoptosis, and inhibited the proliferation of renal cancer cells. Int J Mol Med. 2020 Feb;45(2):315-323
Renal cancer cell line ACHN 0.5-50 µM 96 h 9-ING-41 alone induced cell cycle arrest and apoptosis, and inhibited the proliferation of renal cancer cells. Int J Mol Med. 2020 Feb;45(2):315-323
SW480 cells 2 μM 3 h Evaluate the effect of 9-ING-41 on SW480 cell growth; results showed SW480 cells were resistant to pure 9-ING-41, but the growth inhibitory effect of the combination of 5-FU and oxaliplatin was more pronounced in the presence of 9-ING-41 Front Pharmacol. 2021 Dec 9;12:777114
RKO cells 2 μM 3 h Evaluate the effect of 9-ING-41 on RKO cell growth; results showed RKO cells were sensitive to 9-ING-41, and it significantly enhanced the growth inhibitory effect of 5-FU and oxaliplatin Front Pharmacol. 2021 Dec 9;12:777114
HT-29 cells 2 μM 3 h Evaluate the effect of 9-ING-41 on HT-29 cell growth; results showed HT-29 cells were resistant to transient inhibition of GSK-3β by 9-ING-41 Front Pharmacol. 2021 Dec 9;12:777114
CD8+ T cells 1 µM 48 h To evaluate the effect of 9-ING-41 on cytokine secretion by CD8+ T cells. Results showed increased secretion of IFN-γ, granzyme B, and TRAIL, and decreased concentrations of VEGF, TNF-alpha, and CCL5/RANTES. Cancer Biol Ther. 2022 Dec 31;23(1):417-423
STS cell lines 0.1 to 0.6 µM 72 h To examine the antitumor effect of 9-ING-41 on STS, results showed that 9-ING-41 significantly suppressed the viability of all 20 STS cell lines by inhibiting GSK3β J Hematol Oncol. 2021 Dec 2;14(1):202

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice BC-1 and BC-2 PDX models Intraperitoneal injection 70 mg/kg Twice weekly for four weeks Enhanced the antitumor effect of CPT-11, leading to tumor regression Cancer Lett. 2016 Oct 1;380(2):384-392
NSG mice IB115 liposarcoma model Intraperitoneal injection 70 mg/kg Two injections, until day 38 To evaluate the in vivo antitumor effect of 9-ING-41 alone or in combination with chemotherapy, results showed that the combination treatment significantly reduced tumor volume J Hematol Oncol. 2021 Dec 2;14(1):202

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.47mL

0.49mL

0.25mL

12.37mL

2.47mL

1.24mL

24.73mL

4.95mL

2.47mL

References

 

Historical Records

Categories